Source:

Heijstek
MW
,
Kamphuis
S
,
Armbrust
W
, et al
.
Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis
.
JAMA
.
2013
;
309
(
23
):
2449
2456
; doi:
https://doi.org/10.1001/jama.2013.6768

Investigators from 5 Dutch medical centers conducted a randomized open-label clinical trial to evaluate the immunogenicity and safety of the measles-mumps-rubella (MMR) booster vaccination in children with juvenile idiopathic arthritis (JIA) who had previously received their primary MMR vaccination. The study was conducted in patients 4 to 9 years old to allow patients in the nonvaccinated arm to receive their MMR booster on the normal schedule (age 9–10 years in Netherlands).

Patients who were on a biologic treatment for JIA (ie, etanercept, anakinra) had this treatment held for 5 half-lives before receiving the booster, and for an additional 3 to 7 days after receiving the vaccine. The primary outcome measure, JIA disease activity, was evaluated using the JADAS-27 measure, which is a composite score based on the following components: number of joints with active arthritis, physician global assessment of activity, patient overall global well-being score, and normalized ESR. Lower JADAS-27 scores are indicative of less disease activity. Secondary outcome measures included the number of flares that occurred during the 1-year follow-up. To assess the immunogenicity of the booster vaccination, the level of MMR-specific IgG antibodies was determined at 12 months after enrollment. Cut-off values for seroprotection against each disease were selected prior to patient enrollment; the proportion of participants with seroprotection in each treatment group 12 months after enrollment was compared.

A total of 137 JIA patients were randomized and outcome data evaluated in 131; 63 received MMR booster and 68 were randomized to no vaccination. Among the 131 study patients, 72 (55%) had the persistent oligoarthritis pattern of JIA, followed by the polyarticular subtype (21%); 11% had systemic JIA. Almost half of the patients were on methotrexate (MTX), and 11% were on a biologic agent (either TNF antagonist or interleukin-1 receptor antagonist). Children in both study arms had a low JADAS score at baseline, with most having no active joints. Participants in the 2 study arms were similar for mean age, disease duration, and JIA subtype pattern.

No significant change occurred in JADAS-27 during follow-up for either arm, or for patients on MTX or biologic treatment. Similar percentages of patients in each arm had a disease flare. Study patients randomized to the booster vaccination group had significantly higher MMR antibody concentrations at 12 months compared to controls, and tended to have a higher frequency of seroprotection against measles, rubella, and mumps than those in the control group (100%, 100%, 97%, and 92%, 94%, and 81%, respectively). There were no serious adverse effects related to MMR vaccination and no infections related to attenuated virus occurred, including in the 9 patients receiving biologic treatment.

The authors conclude that MMR booster vaccination did not lead to worse JIA disease activity and was immunogenic.

Dr Li...

You do not currently have access to this content.